In a previous work, Yu and colleagues investigated the use of the chimeric anti-CD138 mAb 1610 in in vitro studies and showed that it is able to induce ADCC cytotoxicity in CD138+ MM cells through NK cell-mediated activation (162). This evidence concerns the gene SDC1 and Miyoshi myopathy.